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Background: Abundant research suggested that the cancer cells avoid destruction by the immune system through
down-regulation or mutation of death receptors. Therefore, it is very important that finding the agents that increase
the death receptors of cancer cells. In this study, we demonstrated that the snake venom toxin from Vipera lebetina
turanica induce the apoptosis of colon cancer cells through reactive oxygen species (ROS) and c-Jun N-terminal
kinases (JNK) dependent death receptor (DR4 and DR5) expression.
Methods: We used cell viability assays, DAPI/TUNEL assays, as well as western blot for detection of apoptosis
related proteins and DRs to demonstrate that snake venom toxin-induced apoptosis is DR4 and DR5 dependent.
We carried out transient siRNA knockdowns of DR4 and DR5 in colon cancer cells.
Results: We showed that snake venom toxin inhibited growth of colon cancer cells through induction of
apoptosis. We also showed that the expression of DR4 and DR5 was increased by treatment of snake venom toxin.
Moreover, knockdown of DR4 or DR5 reversed the effect of snake venom toxin. Snake venom toxin also induced
JNK phosphorylation and ROS generation, however, pretreatment of JNK inhibitor and ROS scavenger reversed the
inhibitory effect of snake venom toxin on cancer cell proliferation, and reduced the snake venom toxin-induced
upregulation of DR4 and DR5 expression.
Conclusions: Our results indicated that snake venom toxin could inhibit human colon cancer cell growth, and
these effects may be related to ROS and JNK mediated activation of death receptor (DR4 and DR5) signals.
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Colorectal cancer is one of the most common fetal can-
cers, causing the second cancer-related death [1]. Al-
though a number of chemotherapeutic agents such as
capecitabine, irinotecan, oxaliplatin, and leucovorin-
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reproduction in any medium, provided the orchemotherapy in advanced colorectal cancer [2-4], re-
sistance to chemotherapy remains a major problem in
the therapy of this cancer and new approaches are ur-
gently required [5]. Moreover, it is reported that most
chemotherapeutics have marked cytotoxic effects on
normal cells [6,7]. Recently, a body of evidence sug-
gested that down-regulation or mutation of death recep-
tors (DRs) might be a mechanism by which cancer cells
avoid destruction by the immune system [8,9]. Breaking
such resistance was rendered by some anticancer drugs
that enhance death receptor expression and aggregation
at the surface of tumor cells, thereby increasing the apop-
totic response to death receptor ligands [8,9]. Therefore, it. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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receptors of cancer cells for decrease of resistance.
Apoptosis is the best characterized form of programmed
cell death and is an intracellular suicide program posses-
sing morphologic characteristics and biochemical features,
including chromatin condensation, nuclear DNA fragmen-
tation, cell shrinkage, membrane blebbing, and the forma-
tion of apoptotic bodies [10,11]. It is an important process
in maintaining homeostasis which can be triggered by
many factors like radiation and chemotherapeutics drugs
[12]. To date, two major apoptotic pathways have been
described as follows: the intrinsic mitochondrion-initiated
pathway and the extrinsic death receptor-mediated path-
way [13,14]. In the intrinsic (mitochondrial) pathway,
proapoptotic proteins result in a net increase of free cyto-
solic cytochrome C. Once released, cytochrome c interacts
with adenosine triphosphate, apoptosis-activating factor-1
(Apaf-1) and procaspase 9 to form the apoptosome. The
apoptosome cleaves and activates caspase 9, which leads
to caspases 3, 6, and 7 activation, thus stimulating apop-
tosis [15,16]. The extrinsic apoptotic pathway originates at
membrane death receptors such as DR4 (TRAIL-R1), and
DR5 (TRAIL-R2) and Fas (CD95/APO-1) [17-19]. In this
extrinsic pathway, binding of tumor necrosis factor (TNF),
TNF-related apoptosis-inducing ligand (TRAIL), or Fas
ligands to their receptors, in association with adaptor
molecules such as Fas-associated death domain (FADD)
or TNF receptor-associated death domain, leads to cleav-
age and activation of initiator caspase 8 and 10, which in
turn cleaves and activates executioner caspases 3, 6, and 7
culminating in apoptosis. Recently, the use of death recep-
tor ligands as therapeutic agents has come under scrutiny
[17-21].
The death receptors (DRs) are induced through react-
ive oxygen species (ROS), mitogen activated protein
kinases (MAPKs) and p53 dependent pathway [22-25]. It
has been reported that DRs are induced through ROS
dependent pathways by several chemotherapeutic agents
[22-25]. Previous studies demonstrated that the curcu-
min induced renal cancer cell apoptosis by induction of
DR5 accompanied with the generation of ROS and sensi-
tized TRAIL induced apoptosis. However this apoptotic
effect and DR5 upregulation were blocked by treatment
of N-acetylcysteine (NAC), a ROS scavenger [22]. Other
groups also showed that baicalein and ursolic acid (UA)
enhanced ROS-mediated DR4 or/and DR5 expression in
colon cancer cells, and thereby enhanced TRAIL-induced
apoptosis which was reversed by NAC [23,24]. Several
reports demonstrated that MAPKs, including extracellular
signal-regulated kinases (ERK)1/2, p38 MAPK, and Jun
N-terminal kinase (JNK) also have been shown to mediate
up-regulation of DRs [24,25]. LY303511 upregulated DR4
and DR5 by activation of JNK and ERK pathways and
enhanced TRAIL induced apoptosis in neuroblastomacells, and the induction of DRs and TRAIL induced apop-
tosis were reduced by treatment of JNK and ERK inhibi-
tors [25]. It was also reported that the bisindolylmaleimide
induced DR5 expression by JNK and p38 pathways in
astrocytoma cells [26].
Many researchers have believed that natural snake
venom toxins are useful biological resource, containing
several pharmacologically active components that could
be of potential therapeutic value [27]. Recently, a lot of
effort has been taken to develop snake venom toxin into
therapeutics such as anti-hypertensive, anti-coagulant
and anti-stroke drugs [28]. Particularly snake venom
toxin from Vipera lebetina turanica was previously
demonstrated as a possible chemotherapeutic against for
growth of human prostate cancer cell and neuroblast-
oma cell through induction of apoptosis via modulating
the expression of apoptosis regulatory proteins and ROS
dependent mechanisms [27,29]. However, the apoptotic
effect of snake venom toxin on colon cancer cells
through induction of DR expression has not been stud-
ied yet. In this study, we evaluated effects of snake
venom toxin obtained from Vipera lebetina turanica on
colon cancer cells. In particular, we determine the cap-
acity of the venom toxin to suppress colon cancer cell
growth by enhancing expression of death receptors
through ROS and JNK pathway.
Methods
Materials
Snake venom toxin from Vipera lebetina turanica was
purchased from Sigma (St. Louis, MO). N-acetycysteine
and SP600125 were purchased from Sigma. Soluble Re-
combinant human Apo2L/TRAIL was purchased from
Peprotech (Rocky Hill, NJ). Small interfering (si) RNA
species for death receptor (DR4 and DR5) and non-
targeting control siRNA were purchased from Bioneer
(Daejeon, Korea), and death receptor 4 (DR4) was pur-
chased from Santa Cruz Biotechnology Inc. (Santa Cruz,
CA, USA)
Cell culture and regents
HCT116, HT-29 colon cancer cells and CCD18 Co nor-
mal colon cell were obtained from the American Type
Culture Collection (Manassas, VA). Cells were grown at
37°C in 5% CO2 humidified air in RPMI 1640 medium
supplemented with 10% fetal bovine serum (FBS), 100
U/ml penicillin, and 100 μg/ml streptomycin. RPMI1640,
penicillin, streptomycin and FBS were purchased from
Gibco Life Technologies (Grand Island, NY).
Cell viability
To determine viable cell numbers, the HCT116, HT-29
colon cancer cells and CCD18 Co normal colon cells
were seeded onto 24-well plates (5 × 104 cells/well). The
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5 min at 1500 rpm, resuspended in 10 ml of phosphate-
buffered saline (PBS), and 0.1 ml of 0.2% trypan blue
was added to the cell suspension in each solution
(0.9 ml each). Subsequently, a drop of suspension was
placed in a Neubauer chamber, and the living cancer
cells were counted. Cells that showed signs of trypan
blue uptake were considered to be dead, whereas those
that excluded trypan blue were considered to be viable.
Each assay was carried out in triplicate.
Apoptosis evaluation
Detection of apoptosis was done as described elsewhere
[27]. In short, cells were cultured on 8-chamber slides.
The cells were washed twice with PBS and fixed by incu-
bation in 4% paraformaldehyde in PBS for 1 h at room
temperature. TdT-mediated dUTP nick and labeling
(TUNEL) assays were performed by using the in situ
Cell Death Detection Kit (Roche Diagonostics GmbH,
Mannheim, Germany) according to manufacture’s
instructions. Total number of cells in a given area was
determined by using DAPI staining. The apoptotic index
was determined as the number of TUNEL-positive
stained cells divided by the total cell number counted
x100.
Western blotting
Western blot analysis was performed as described previ-
ously [27]. To prepare the cytosolic extract, the cells
were harvested and suspended in an ice-cold solution
containing 20 mM HEPES (pH 7.5), 1.5 mM MgCl2,
10 mM KCl, 1 mM EDTA, 1 mM EGTA, 1 mM DTT,
0.1 mM phenylmethylsulfonyl fluoride, 10 μg/ml leupep-
tin, 10 μg/ml aprotinin, 10 μg/ml pepstatin, and
250 mM sucrose. The cells were disrupted using a
Dounce homogenizer. The samples were centrifuged at
1,500 g for 5 min at 4°C to remove nuclei and intact
cells. The supernatant was centrifuged at 105,000 g for
30 min at 4°C. The resulting supernatant was used as
the soluble cytosolic fraction. The membranes were
immunoblotted with the following primary antibodies:
mouse monoclonal antibodies directed against cleaved
caspase-8 (1:1000 dilutions; Cell Signaling Technology,
Beverly, MA) cytochrome-C, p53 and bax (1:500 dilu-
tions; Santa Cruz Biotechnology Inc. CA, USA.), and
rabbit polyclonal antibodies directed against ERK,
phospho-ERK and JNK (1:500 dilutions; Santa Cruz Bio-
technology Inc. CA, USA.), and cleaved caspase-3, -9
and phospho-JNK (1:1000 dilutions; Cell Signaling Tech-
nology, Beverly, MA). The blot was then incubated with
the corresponding anti-mouse/rabbit immunoglobulin
G-horseradish peroxidase-conjugated secondary anti-
body (Santa Cruz Biotechnology Inc. CA, USA). Immu-
noreactive proteins were detected with the EnhancedChemiluminescence Western blotting detection system
(Amersham Pharmacia Biotech, Inc., Buckinghamshire,
UK). The relative density of the protein bands was
scanned by densitometry using MyImage (Seoulin Bio-
science Inc., Seoul, Korea) and quantified by Labworks
4.0 software (UVP Inc., Upland, CA, USA).
Transfection
HCT116, HT-29 colon cancer cells (5 × 104 cells/well)
were plated in 24-well plates and transiently transfected
with 0.4 μg of the empty vector or the 100 nM of nega-
tive siRNA, DR4 or DR5 siRNA per well, using a mix-
ture of plasmid and the WelFect-EX PLUS reagent in
OPTI-MEM, according to manufacturer's specification
(WelGENE, Seoul, Korea).
RT–PCR
Total RNA was extracted by RNeasy kit (Qiagen, Valencia,
CA, USA). The RT reaction was performed using RNA to
cDNA Kit (Applied Biosystems, Foster City, CA, USA). The
PCR reaction was performed with cDNA as a template
using the primers below after an initial 1-min denaturation
at 96°C, followed by the indicated cycles of 96°C for 1 min,
60°C or 63°C for 1 min and 72°C for 1 min. The used PCR
primers were 5’-ACCAATGCCACAAAGGAAC-3’ and
5’-CTG CAATTGAAGCACTGGAA-3’ for the human
TNF receptor 1, 5’-CTCAGGAGCATG GGGATAAA-3’
and 5’-AGCCAGCCAGTCTGACATCT-3’ for the human
TNF receptor-2, 5’-ATGGCGATGGCTGCGTGTCCTG-3’
and 5’-AGCGCCTCCTGGGTCTCGGGGTAG-3’ for the
human DR3, 5’-ACTTTGGTTGTTCCGTTGCTG TTG-
3’ and 5’-GGCTTTCCATTTGCTGCTCA-3’ for the human
DR4, 5’-TGGAACAACGGGGACAGAACG-3’ and 5’-GCAG
CGCAAGCAGAAAAGGAG-3’ for the human DR5, 5’-
AAGCCGGGGACC AAGGAGACAGACAAC-3’ and 5’-TG
CCGGGGCCCTTTTTCAGAG T-3’ for the human DR6 and
5’-CAAAGCCCATTTTTCTTCCA-3’ and 5’-GACAAAGCC
ACCCCAAGTTA-3’ for human FAS, 5’-CAGCTCTTCC
ACCTACAG AAG G-3’ and 5’-AAGATTGAACACTG
CCCCCAGG-3’ for FasL, 5'-AGACCTGCGTGCT
GATCGTG-3' and 5'-TTATTTTGCGGCCCAGAGCC
-3' for human TRAIL, 5’-GAAGGTGAAGGxTCGG




Generation of ROS was assessed by 2, 7- dichlorofluor-
escein diacetate (DCFH-DA, Sigma Aldrich, St Louis,
MO, USA), an oxidation-sensitive fluorescent probe.
Intracellular H2O2 or low-molecular-weight peroxides
can oxidize 2, 7-dichlorofluorescein diacetate to the
highly fluorescent compound dichlorofluorescein (DCF).
Briefly, cells were plated in 6 well plates (5X104), and
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venom toxin (0.1-1 μg/ml) for 30 min. After the cells
were trypsinized, the 1x104 cells were plated in black
96 well plate and incubated with 10 μM DCFH-DA at
37°C for 4 h. The fluorescence intensity of DCF was
measured in a microplate-reader at an excitation
wavelength of 485 nm and an emission wavelength of
538 nm.
Statistical analysis
The data were analyzed using the GraphPad Prism 4 ver.
4.03 software (GraphPad Software, La Jolla, CA, USA).
Data are presented as mean± SD. The differences in all
data were assessed by one-way analysis of variance
(ANOVA). When the P value in the ANOVA test indi-
cated statistical significance, the differences were assessed
by the Dunnett’s test. A value of p< 0.05 was considered
to be statistically significant.
Results
Effect of snake venom toxin on the growth of human
colon cancer cells
To evaluate an effect of the snake venom toxin from
Vipera lebetina turanica on the growth of colon cancer
cells, we analyzed the cell viability by direct counting
viable cells in Neubauer chamber. Snake venom toxin
(0.1-1 μg/ml) inhibited HCT116 and HT-29 colon cancer
cell viability dose dependently. The IC50 values of snake
venom toxin in HCT116 and HT-29 is 1.14 μg/ml and
1.24 μg/ml, respectively. However, there are no remark-
able changes in CCD18 Co normal colon cell viability
(Figure 1A). To determine if the inhibition of cell viability
by snake venom toxin was due to the induction of apop-
tosis, we evaluated the changes in the chromatin morph-
ology of cells by using DAPI staining followed by TUNEL
staining assays, and then the double labeled cells were
analyzed by fluorescence microscope. The cells were trea-
ted with various concentrations of snake venom toxin
(0.1, 0.5 and 1 μg/ml) for 24 h. DAPI-stained TUNEL-
positive cells were concentration-dependently increased
and highest concentration of snake venom toxin (1 μg/ml)
caused most of cells TUNEL-positive, and the apoptosis
rates were 51.25 ± 2.6% in HCT116 cells and 50.43± 1.4%
in HT-29 cells (Figure 1B). These results demonstrated
that snake venom toxin treatment strongly induced apop-
tosis in colon cancer cells.
Effect of snake venom toxin on the ROS generation in
human colon cancer cells
Several chemotherapeutic agents induce apoptosis by in-
crease of ROS [30,31]. We investigated whether snake
venom toxin also induced ROS in colon cancer cell lines,
since we had found that ROS is implicated in the snake
venom toxin-induced neuroblastoma cell death [29].Thus, we determined the role of ROS in mediating SVT-
induced apoptosis of HCT116 and HT-29 cells by meas-
uring ROS levels after treatment of varying concentrations
of snake venom toxin (0.1, 0.5 and 1 μg/ml) for 30 min.
As shown in Figure 2A, snake venom toxin increased
ROS levels in a dose-dependent manner in both HCT116
and HT-29 cells.
Effect of snake venom toxin on the expression of death
receptors in human colon cancer cells
Several studies demonstrated that the ROS generation is
involved in DR4 and DR5 upregulation by treatment of
chemotherapeutic agents such as curcumin, baicalein
and ursolic acid [22-24]. We investigated the possible in-
volvement of ROS in the expression of death receptors
after treatment of snake venom toxin. We evaluated
changes in expression of several death receptors and
their ligands in HCT116 and HT-29 colon cancer cells
using RT-PCR. Consistent with the increase of apoptosis,
the expressions of DR4 and DR5 was significantly
increased by treatment of snake venom toxin in a dose-
dependent manner in HCT116 and HT-29 cells. But ex-
pression of other death receptors such as TNF-R1, TNF-
R2, DR3, DR6 and Fas and death receptor ligands such
as FasL and TRAIL was not changed by treatment of
snake venom toxin (Additional file 1: Figure 1). The
increased expression of DR4 and DR5 was also con-
firmed by western blotting (Figure 2B). Taken together,
these results indicated that snake venom toxin induced
apoptosis by up-regulation of DR4 and DR5 in colon
cancer cells.
Effect of snake venom toxin on the expression of
caspase-3, 8, 9 and bax in human colon cancer cells
To elucidate the relationship between apoptosis and the
expression of apoptosis regulatory protein by snake
venom toxin, expression of caspase-3, 8, 9, Bax and cyto-
chrome C was investigated since these are DR related
down signal cell death proteins. Cells were treated with
snake venom toxin (0.1-1 μg/ml), and whole-cell extract
was subjected to Western blotting. An increase in the
cleavage of caspase-3 (including cleaved caspase-3),
caspase-8 (including cleaved caspase-8) and caspase-9
(including cleaved caspase-9) was observed (Figure 3A),
Bax/Bcl2 ration was significantly increased (Figure 3B),
and the cytochrome C was increased in cytosol extract
(Figure 3C) in HCT116 and HT-29 colon cancer cells.
Effect of knockdown of DR4 and DR5 in snake venom
toxin-induced apoptosis
We next investigated the effect of knockdown of DR4
and DR5 on the snake venom toxin induced colon can-
cer cell viability inhibition using DR4 or DR5 specific
siRNA to confirm that the DR4 and DR5 play a critical
Figure 1 Effect of snake venom toxin on viability of human colon cancer cells. HCT116 cells and HT-29 cells were inoculated into 24-well
plates (5 × 104 cells/well) and thereafter treated with snake venom toxin (0.1, 0.5, 1 μg/ml) at 37°C for 24 h. a, Cell viability of HCT 116 cell, HT-29
cell and CCD18Co cells was determined by direct counting viable cells in Neubauer chamber. The results were expressed as a percentage of
viable cells. b, Analysis of apoptosis by TUNEL assay. The colon cancer cells (HCT116 and HT-29) were treated with snake venom toxin (0.1-1 μg/
ml) for 24 h, and then labeled with TUNEL solution. Total number of cells in a given area was determined by using DAPI nuclear staining
(fluorescent microscope). The apoptotic index was determined as the DAPI-stained TUNEL-positive cell number/total DAPI stained cell number
(magnification, 200x). Columns, means of three experiments, with triplicates of each experiment; bars, SD. *, p <0.05, significantly different from
snake venom toxin-untreated control cells.
Park et al. BMC Cancer 2012, 12:228 Page 5 of 12
http://www.biomedcentral.com/1471-2407/12/228role on cell death. Figure 4A revealed that the effect of
snake venom toxin-induced cell death was effectively
abolished in cells transfected with either DR4 or DR5
siRNA (100 nM) in both HCT116 and HT-29 cells.
Interestingly, knockdown of DR4 more significantly
reversed the growth inhibitory effect of snake venom
toxin in HCT116 and HT-29 cells. We also showed that
the caspase-3 activation was inhibited by treatment of
DR4 or DR5 siRNA accompanied with downregulation
of DR4 or DR5 proteins (Figure 4B). These results indi-
cate that DR4 and DR5 play a major role in apoptotic
colon cancer cell death by snake venom toxin.
Involvement of JNK pathway and ROS in the induction of
death receptors and apoptosis by snake venom toxin
We found that the JNK was activated by treatment of
snake venom toxin, but not ERK and p38 in HCT116
and HT-29 colon cancer cells (Figure 5A). To further in-
vestigate whether JNK plays a critical role in snake
venom toxin-induced up-regulation of DR4 and DR5, we
pretreated the colon cancer cells with SP600125, a JNKinhibitor (5 and 10 μM) for 1 h, and then these cells
treated with snake venom toxin (1 μg/ml) for 24 h to as-
sess cell viability and DR4 and DR5 expression. As a re-
sult, JNK inhibitor abolished snake venom toxin-induced
inhibition of cell viability (Figure 5B) and suppressed the
snake venom toxin-induced up-regulation of DR4 and
DR5 (Figure 5C), suggesting that JNK pathway may be
involved in snake venom toxin-induced apoptosis and
upregulation of DRs. Because we already showed that
snake venom toxin (0.1-1 μg/ml) induced ROS in a
dose-dependent manner in HCT116 and HT-29 cells in
Figure 2A, we further investigated whether ROS plays a
role in snake venom toxin-induced up-regulation of DR4
and DR5. We pretreated with NAC, an antioxidant (1
and 10 mM) for 1 h in HCT116 and HT-29 cells, and
then treated with snake venom toxin (1 μg/ml) for
30 min to assess cell viability and DR4 and DR5 expres-
sion. It was found that NAC abolished snake venom
toxin-induced inhibition of cell viability (Figure 6A) and
suppressed the snake venom toxin-induced up-regulation
of DR4 and DR5, and JNK phosphorylation (Figure 6B),
Figure 2 Effect of snake venom toxin on ROS generation and the expression of death receptors in human colon cancer cells. a, Effect
of snake venom toxin on ROS generation by treatment of snake venom toxin in colon cancer cells. After treatment of snake venom toxin for
30 min, the cells were incubated with 10 μM DCF-DA at 37°C for 4 h, and then washed twice with PBS. The fluorescence intensity of DCF was
measured in a microplate-reader at an excitation wavelength of 485 nm and an emission wavelength of 538 nm. b, Two colon cancer cells,
HCT116 cells and HT-29 cells were treated with snake venom toxin (0.1, 0.5, 1 μg/ml) at 37°C for 24 h, and equal amounts of total proteins
(50 μg/lane) were subjected to 12% SDS-PAGE. Expression of DR4, DR5 and β-actin was detected by Western blotting using specific antibodies. β-
actin protein was used an internal control. Each band is representative for three experiments. Columns, means of three experiments, with
triplicates of each experiment; bars, SD. *, p <0.05, significantly different from non treated control group.
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induced apoptosis and upregulation of DRs, and activation
of JNK. Taken together, these results indicated that the JNK
and ROS pathway are critical in induction of DR4 and DR5
expression, and DR4 and DR5 mediated apoptosis by snake
venom toxin in colon cancer cells.
Discussion
We showed that snake venom toxin inhibited HCT116
and HT-29 colon cancer cell growth through apoptosis.
Our study also showed that this effect was associated
with the JNK and ROS-mediated increased expression of
the DR4 and DR5. The TRAIL receptors, DR4 and DR5
are also expressed in colon carcinomas and their expres-
sions are increased as tumor cells acquire malignant po-
tential [32-35]. Colon cancer cells and tumor are
relatively sensitive to TRAIL-mediated apoptosis, but
normal colonic epithelium are resistant to TRAIL-
mediated apoptosis [36-38]. Due to its selective ability
for killing of tumor cells with little side effects on normal
cells, the activators of TRAIL pathway have emerged as
attractive candidates for cancer therapy. It has been
shown that TRAIL-induced apoptosis can be enhanced
by chemotherapy in several in vitro and xenograft modelsof cancer, an effect reported to be mediated through
increased DR4 and DR5 expression [36-38]. For example,
Garcinol derived from dried rind of the fruit Garcinia
indica has a synergistic anticancer effect with TRAIL by
up-regulate the DR4 and DR5 in human colon cancer
cells [36]. Celastrol, a triterpenoid isolated from the trad-
itional Chinese medicine enhances TRAIL-induced apop-
tosis through the upregulation of DRs in colon cancer
cells [37]. Diosgenin, a steroid saponin present in fenu-
greek (Trigonella foenum graecum) induced apoptosis in
colon cancer cells and sensitized colon cancer cells to
TRAIL by induction of DR5 [38].
Recent studies indicate that DR levels can be enhanced
by endogenous induction or exogenous overexpression.
Several genotoxic and nongenotoxic agents can induce
apoptosis by increasing endogenous DRs [39]. On the
other hand, exogenously overexpressed DRs, without
concomitant up-regulation in its ligand levels, have been
shown to be associated with induction of apoptosis
[40,41]. In this study, our results demonstrated that
SVT-induced apoptosis is coupled with DR4 and DR5.
Similar to previous studies, we showed that the snake
venom toxin induced DR4 and DR5 in colon cancer
cells, however the expression of Fas and other death
Figure 3 Effect of snake venom toxin on the expression of apoptosis regulatory proteins in human colon cancer cells. a, HCT116 cells
and HT-29 cells were treated with different concentrations (0.1, 0.5, 1 μg/ml) of snake venom toxin at 37°C for 24 h. Equal amounts of total
proteins (50 μg/lane) were subjected to 12% SDS-PAGE. Expression of cleaved caspase-3, cleaved caspase-8 and cleaved caspase-9 was detected
by Western blotting using specific antibodies. b, HCT116 cells and HT-29 cells were treated with different concentrations (0.1, 0.5, 1 μg/ml) of
snake venom toxin at 37°C for 24 h. Equal amounts of total proteins (50 μg/lane) were subjected to 12% SDS-PAGE. Expression of Bax, Bcl2 and
β-actin was detected by Western blotting using specific antibodies. Columns, means of three experiments, with triplicates of each experiment;
bars, SD. *, p <0.05, significantly different from non treated control group. c, HCT116 cells and HT-29 cells were treated with different
concentrations (0.1, 0.5, 1 μg/ml) of snake venom toxin at 37°C for 24 h. And cytosol extract was prepared as described in methods. Equal
amounts of total proteins (50 μg/lane) were subjected to 12% SDS-PAGE. Expression of cytochrome C and β-actin was detected by Western
blotting using specific antibodies. β-actin protein was used an internal control. Each band is representative for three experiments.
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that treatment of DR4 or DR5 siRNA reversed snake
venom toxin-induced inhibition of cell viability, thus, the
inhibitory effect of snake venom toxin could be related
with the increase of DR4 and DR5 expression. Caspases
play a critical role in apoptosis [42]. Caspase-8 is the
most proximal caspase that transmits apoptotic signals
originating from the DRs. Activation of caspase- 8
results in activation of downstream caspases such as
caspase-3, -6, or −7 and triggering Bax, cytochrome C
and caspase-9 apoptosis signal [43]. We showed that the
caspase-8 was activated by treatment of snake venom
toxin, accompanied with the activation of caspase-3 and
−9, expression of Bax and cytosolic release of cyto-
chrome C in a dose dependent manner. Other research-
ers demonstrated that the Ursodeoxycholic acid (UDCA)induces apoptosis in human gastric cancer cells, and this
effect is dominantly mediated by activation of caspase-3,
-6 and −8 through increased expression of DR5 [44].
Tocotrienols, a naturally occurring form of vitamin E,
also induced apoptosis of breast cancer cells by induced
activation of caspase-3 -8 and −9 by upregulation of
DR5 [43]. For these reseasons, snake venom toxin may
be effective for inducing colon cancer cell death through
activation of DR mediated cell death signals.
It has been significantly proposed that the ROS gen-
erations are involved in DR4 and DR5 upregulation by
chemotherapeutic agents [22-25]. Other previous studies
demonstrated that the expression of DR4 and DR5 was
induced by several anti-cancer coumpunds shch as cur-
cumin, baicalein and ursolic acid accompanied with the
generation of ROS, and these DR4 and DR5 upregulation
Figure 4 Effects of DR4 or DR5 knockdown on snake venom toxin induced cell viability inhibition and caspase-3 activation. a, HCT116
cells and HT-29 cells were transfected with non targeting control siRNA or DR4 or DR5 siRNA (100 nM) as described in Methods for 24 h. Then,
implemented snake venom toxin was treated (1 μg/ml) for another 24 h. Thereafter, cell viability was measured by direct counting after trypan
blue staining. b, Equal amounts of total proteins (50 μg/lane) were subjected to 12% SDS-PAGE. Expression of DR4, DR5, cleaved caspase-3 and
β-actin was detected by Western blotting using specific antibodies. β-actin protein was used an internal control. Each band is representative for
three experiments. Columns, means of three experiments, with triplicates of each experiment; bars, SD. *, p <0.05, significantly different from non
treated control group. #, p <0.01 significantly different from sc siRNA -treated group.
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with these result, we showed that snake venom toxin
induced generation of ROS, and the antioxidant NAC
abolished the upregulation of DR4 and DR5 induced by
snake venom toxin, and cell growth inhibitory effect by
SVT was also reversed by treatment of NAC. Several stud-
ies demonstrated that ROS is also significant for the acti-
vation of JNK pathway in cancer cell apoptosis. In fact,
ROS-dependent activation of JNK is involved in apoptosis,
autophage, innate immunity and lifespan limitation
[45,46]. Indeed, the activities of ROS and JNK induced by
death receptors appear to be linked, both being obligatory
participants in the same death-inducing pathway triggered
by these receptors [47,48]. It has been demonstrated that
several chemotherapeutic agents such as surfactin and
celastrol induced apoptosis by induction of ROS throughactivation of JNK pathway in cancer cells [49,50]. Thus it
is also possible that increased ROS by snake venom toxin
activates JNK pathway which resulted in upregulation of
DR4 and DR5 leading to increase cell death signals. In this
study, we showed that the JNK is activated by treatment
of snake venom toxin in both HCT116 and HT29 cell
lines. Furthermore, JNK inhibitor SP600125 abolished
snake venom toxin-induced DR4 and DR5 expression. We
also showed that the NAC abolished snake venom toxin-
induced JNK phosphorylation accompanied with the acti-
vation of DR4 and DR5. These data suggest that activated
ROS and consequent activation of JNK could be involved
in increased DR4 and DR5 expression. Similar to our
results, other groups showed that the tocotrienols induced
apoptosis of breast cancer cells by upregulation of DR5 by
activation of JNK, p38 MAPK and C/EBP homologous
Figure 5 Effect of JNK pathway on the upregulation of DR4 or DR5, and cell death by snake venom toxin. a, Effect of snake venom toxin
on the expression of MAPK proteins in colon cancer cells. HCT116 cells and HT-29 cells were treated with snake venom toxin for 24 h and whole
cell extracts were analyzed by western blotting using the relevant antibodies. b, Effect of SP600125 on the cell viability in snake venom toxin
treated cancer cells. Cells were pretreated with SP600125 (0, 5, 10 μM) for 1 h and then treated with snake venom toxin for 24 h. The results were
expressed as a percentage of viable cells. c, Effect of JNK inhibitor (SP600125) on the expression of death receptors. Cells were pretreated with
SP600125 (10 μM) for 1 h, and then cells were treated with snake venom toxin for 24 h, and whole cell extracts were analyzed by Western
blotting using DR4, DR5, p-JNK and β-actin antibodies. Each band is representative for three experiments. Columns, means of three experiments,
with triplicates of each experiment; bars, SD. *, p <0.05, significantly different from non treated control group. #, p <0.01 significantly different
from SVT-treated group.
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reduced the increase in DR5 and CHOP expression, and
blocked tocotrienols-induced apoptosis [43]. It has been
also reported that the LY303511 upregulated DR4 and
DR5 by activation of JNK in neuroblastoma cells, and the
induction of DRs were reduced by treatment of JNK and
ERK inhibitors [25]. It was also reported that the bisindo-
lylmaleimide induced the DR5 by activation of JNK and
p38 pathways in astrocytoma cell death [26]. And like our
studies, other group suggested that melittin, a bee venom
toxin compound enhanced TRAIL-induced apoptosis by
activating JNK/p38 pathway [51].
Transcriptional regulation of DR4 and DR5 is com-
plex, and multiple potential binding sites of various
transcription factors, including p53, are present in the
upstream region of DR4 and DR5 [52]. However, wefound that the p53 is not induced by snake venom toxin
(data not shown). Thus, the induction of DR4 and DR5
by snake venom toxin occurs independent of p53 in
colon cancer cells. Instead, our data indicate that snake
venom toxin-induced upregulation of DR4 and DR5
could be dependent on the ROS and JNK pathway.
Taken together, our results provide the mechanistic
evidence that snake venom toxin treatment results in
induction of apoptosis of colon cancer cells through
ROS and JNK-mediated upregulation of DR4 and
DR5. These results also indicate that snake venom
toxin may sensitize colon cancer cells to the TRAIL
induced apoptosis. Therefore, our results suggest that
the treatment of snake venom toxin could be applic-
able as an anti-colorectal cancer agent, and/or an ad-
juvant agent for other chemotherapeutics.
Figure 6 Effect of ROS on upregulation of DR4 or DR5 through JNK activation by snake venom toxin. a, Effect of antioxidant (NAC) on
the cell viabilty induced by snake venom toxin. Cells were pretreated with various concentratins of NAC (0, 1, 10 mM) for 1 h and then treated
with 1 μg/ml of snake venom toxin for 30 min, and whole cell extracts were analyzed by western blotting using the relevant antibodies. b, Effect
of NAC on the expression of death receptors and JNK phosphorylation. Cells were pretreated with NAC for 1 h, and then cells were treated with
snake venom toxin for 30 min, and whole cell extracts were analyzed by Western blotting using DR4, DR5, p-JNK and β-actin antibodies. Each
band is representative for three experiments. Columns, means of three experiments, with triplicates of each experiment; bars, SD. *, p <0.05,
significantly different from non treated control group. #, p <0.01 significantly different from SVT-treated group.
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We demonstrated here that the snake venom toxin from
Vipera lebetina turanica induced the apoptosis of colon
cancer cells through reactive oxygen species (ROS) and
c-Jun N-terminal kinases (JNK) dependent death recep-
tor (DR4 and DR5) expression.
Additional file
Additional file 1: Figure S1. Effect of snake venom toxin on the
expression of death receptors in human colon cancer cells. HCT116 cells
and HT-29 colon cancer cells were treated with snake venom toxin (0.1,
0.5, 1 μg/ml) at 37 °C for 24 h, and total RNA were extracted and
examined for expressions of TNF-R1, TNF-R2, DR3, -4, -5, -6, TRAIL, Fas,
FasL and GAPDH by RT-PCR. GAPDH was used as an internal control to
show equal RNA loading. Each band is representative for three
experiments.
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